Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 402

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 402
---
301 |     | $         | 3.00 |     |          |     580 |     |             |     903 |
| Series C    |     |                         | 8/29/2023  |     |            | 75,000 |     |             | 73,820 |     | $         | 1.50 |     |          | 107,065 |     |             | 110,731 |
|             |     |                         |            |     |            | 79,251 |     |             | 78,071 |     |           |      |     | $        | 114,259 |     | $           | 120,484 |

In August 2023, the Company closed on the Series C preferred stock financing (the “Series C Offering”) with four new investor groups (“Series C New Investors”) to invest $75.0 million of which $35.0 million was payable upon the first closing in August 2023 (“First Tranche”) in exchange for approximately 23.3 million shares of Series C preferred stock and $40.0 million payable upon the enrollment of the first patient into the Phase 2 clinical trial of LB-102(“Second Tranche”). The Second Tranche closed in January 2024 and the Company issued approximately 26.7 million shares of Series C preferred stock at $1.50 per share for total gross proceeds of $40.0 million. The Company incurred issuance costs of $2.0 million and $1.7 million associated with the closings of the First Tranche and Second Tranche, respectively. Upon the closing of the Series C Offering, $35.7 million principal of the 2020 Notes and 2022 Notes automatically converted to 23.8 million shares of Series C preferred stock at a price of $1.50 per share. As of June 30, 2025 and December 31, 2024, none of the outstanding shares of Preferred Stock had been converted into common stock. Reissuance: Shares of any Preferred Stock that are redeemed or converted will be retired or canceled and may not be reissued by the Company. F-50

LB Pharmaceuticals Inc Notes to Condensed Financial Statements (Unaudited) Common Stock All issued shares of common stock are entitled to vote on a one share/one vote basis. Warrants See Note 3 Fair Value Measurementsfor warrant activity for the six months ended June 30, 2025 and